A total of 1,052 women living with chronic inflammatory diseases were surveyed across Europe (Germany, France, UK, Italy and Spain), the US and Japan. Results presented at EULAR 2018 specifically highlight the experience of women aged 18-45 living with chronic rheumatic diseases (622/1052 participants), including axial spondyloarthritis (axSpA), psoriatic arthritis, and rheumatoid arthritis.
Findings from 622 women across Europe, the US, and Japan with chronic rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (axSpA), suggest that women with chronic rheumatic diseases face unique challenges during their childbearing years that may be linked to decisions to delay pregnancy and interrupt treatment, and that many women of childbearing age with chronic rheumatic diseases experience a lack of guidance and consistent information regarding family planning and treatment during their pregnancy journey and breastfeeding.
Survey findings point to a need for greater awareness of disease management options, earlier consultation with physicians and alignment on best care to optimize outcomes for mother and infant, and a need for greater access to reliable and consistent information.
To support women living with chronic rheumatic diseases as they navigate their childbearing years, UCB is launching the AIM Movement, a global campaign with local reach designed to spread awareness about managing chronic rheumatic diseases throughout all stages of reproductive journey and encourage women to have informed conversations with their healthcare professionals.
UCB is focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,500 people in approximately 40 countries, the company generated revenue of EUR 4.5bn in 2017.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference